Ohishi T, Hishiki T, Baig MS, Rajpoot S, et al. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. PLoS One 2022;17:e0271112.
PMID: 35830431